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he Coming of Age
f Natriuretic Peptides
he Emperor Does Have Clothes!*
lan Maisel, MD, FACC
an Diego, California
ince its approval by the Food and Drug Administration in
ovember 2000, the worldwide uptake of natriuretic pep-
ides (NPs), both in the clinical and research arenas, has
een nothing short of astounding. In the U.S. alone, recent
ollege of American Pathology (CAP) surveys suggest that
pproximately 83% of hospitals use some type of NP testing.
lthough NP testing was originally focused on rapid diag-
osis of patients presenting to the emergency department
ith shortness of breath, clinicians regularly look to NPs for
iagnosing minimally symptomatic or asymptomatic left
entricular (LV) dysfunction, monitoring therapy of pa-
ients hospitalized for heart failure, and using NP levels in
linic to help ascertain when decompensation is present. In
ddition, the importance of B-type natriuretic peptide
BNP) in as a prognostic marker cannot be overstated. In
act, in a population-based prospective community study in
openhagen, measurements of NPs were stronger predic-
ors for cardiovascular disease and death than was
-reactive protein (1).
See page 52
With the widespread popularity of NPs, clinicians have
oiced concern over which NP test to use; how to account
or differences in age, gender, and renal function; and how
est to integrate NP testing into their daily clinical
ractice. The study by Richards et al. (2) in this issue of
he Journal goes a long way to help sort out these issues.
hese investigators are considered one of the world’s
eading investigators in the use of NPs, compared BNP with
TproBNP in more than 1,000 patients with stable isch-
mic heart disease. These two peptides are derived from the
34-amino-acid precursor prepro BNP. Upon stimulation
f a number of triggers, including wall stretch, ventricular
ilation, and/or increased pressures, a 26-amino-acid signal
eptide sequence is cleaved from the precursor’s N-terminus
o produce proBNP. This hormone is further cleaved by a
embrane-bound serine protease (corin) into the inactive
-terminal fragment and the active BNP fragment. The
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the University of California, San Diego, San Diego, California, and the Sano
iego VA Healthcare System, San Diego, California. Research support was provided
y Roche, Bayer. Dr. Maisel is a consultant for Biosite, Inc.uthors demonstrated that both peptides were closely cor-
elated to each other and exhibited parallel changes across
road ranges of age, renal function, and LV ejection
raction. The two peptides performed similarly in the
etection of ejection fractions reduced below 20%, 40%, or
0% in both symptomatic and asymptomatic patients and
ere indistinguishable in their ability to predict 12-month
ll-cause mortality and/or readmission with heart failure.
Thus, it appears that both NPs offer considerable value to
he clinician. The findings of this study suggest that the
nal decision as to which biomarker, BNP or NTproBNP,
ill be used will not necessarily be based on the differences
etween the two peptides, but rather the presence of the
re-existing laboratory equipment necessary to run the
ssay, as well as the perceived need for point-of-care devices
ersus large laboratory platforms. One thing can be said
ith certainty in this regard. Although Richards et al. (2)
ave shown that the two peptides correlate highly, they are
ot interchangeable; in other words, it would be dangerous
or a hospital laboratory to switch from running BNP to
Tpro BNP or vice versa without first making sure that the
linicians using the test were aware of the differences,
specially in terms of absolute values, because NTproBNP
ends to be about 10-fold higher than BNP. In the U.S.,
bout 80% to 90% of current NP testing involves BNP
CAP surveys), whereas in Europe NT proBNP testing is
ore commonly used (percentages not available). Because
NP was the first peptide to be clinically available, experi-
nce with its use as well as the development of accepted
lgorithms have accounted for its increased use in the U.S.
owever, with the recent work by Januzzi et al. (3), along
ith the publication of the PRIDE study, workable clinical
lgorithms for NTproBNP are being developed.
There are several limitations in this study that should be
ommented on. The first is that these patients were stable
nd, as such, strong correlations between the two peptides
ay not hold in the unstable, acutely presenting patient. For
xample, NTproBNP levels can rise in acutely ill patients
especially those who are older and have renal dysfunction)
o extremely high levels of 30,000 pg/ml. Present studies
re focusing on this issue, and algorithms are being devel-
ped that help to risk stratify patients with these high levels.
Additionally, the issues of age and gender may not be as
mportant in diagnosing congestive heart failure (CHF) in
he acutely dyspneic patient. A substudy of the Breathing
ot Properly Trial examined the impact of age, race, and
ender and found that if one assumes that failing to treat
ases of CHF is worse than treating negative cases (false
egatives have more of an impact than false positives), the
ut point should not rise higher than 100 pg/ml, even
hough specificity in older patients might be less (4).
A second limitation in the present study is no fault of the
uthors, but comes with the territory of large correlative
tudies: although NP data correlate across a large spectrum
f renal function or ejection fractions, what does a single NP
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Editorial Comment January 3, 2006:61–4evel at a single place and time in a given patient mean in the
eal world? For instance, with regards to ejection fraction,
everal factors could affect a single NP level (other than
ender, age, and renal function).
Ps from LV versus right ventricle (RV). Although a
ormal RV accounts for small amounts of NP secretion, in
he setting of pulmonary hypertension the RV can secrete
Ps in amounts that correlate to extent of RV dysfunction
5). Many patients with “gray-zone” BNP levels (100 to 500
g/ml) fall into the category of patients with prior lung
isease such as cor pulmonale, whose BNP level is evidence
f RV stretch.
iastolic dysfunction. A number of studies (6,7) have
ade it clear that in patients with established systolic
ysfunction, concomitant diastolic dysfunction will raise NP
evels in proportion to severity, with restrictive filling
attern leading to the greatest increase.
alve disease. A number of recent studies (8,9) demon-
trate that valvular diseases such as aortic stenosis and mitral
egurgitation may present with elevated NP levels, which
ay be important in timing of valve replacement. In fact,
ichards et al. (2) have demonstrated that for any degree of
V dysfunction, BNP levels will be correspondingly higher,
ith worsening degrees of mitral regurgitation.
Wet versus dry.” Any NP level must be interpreted in
ight of whether the patient is at optimum volume status
i.e., euvolemic). Even patients with mild LV impairment
nd low-normal NP levels will have marked increases in NP
evels with decompensation. With interceding conditions
uch as volume overload, ischemia, or atrial fibrillation, NPs
ill rise without a change in ejection fraction.
ariability of measurements. Although current NP assays
ffer precision that ranges from 4% to 12%, this alone does
ot account for apparent variability of NP. In a limited
igure 1. Clinically embedded algorithm for using B-type natriuretic pepti
congestive heart failure; LV  left ventricular. Adapted from Maisel Aumber of patients, Wu et al. (10) found variability near p00% for both assays. More work is being done in this area
o assess the influence of diurnal variation, diet, time of
edication, and so forth.
ntegrating NPs into practice. ACUTE DYSPNEA IN THE
MERGENCY DEPARTMENTS. Trials such at the Breathing
ot Properly multinational study (11) have helped to
stablish the framework for using BNP in the clinical
etting. Figure 1 is an easy-to-follow popular clinical algo-
ithm for using BNP based on data from that study. Figure
shows an algorithm for using NTproBNP for evaluation
f suspected acute CHF based, in large part, on the recent
RIDE study by Januzzi et al. (3).
Natriuretic peptides also should be useful in triaging patients
ith CHF in the emergency department. The Rapid Emer-
ency Department Heart Failure Outpatient Trial (RED-
OT) (12) demonstrated a disconnect between the perceived
everity of CHF cases by emergency physicians and severity as
etermined by BNP levels. B-type natriuretic peptide levels
ere far more significant with regards to outcomes than was
hysician perception of severity, and patients admitted with
HF with BNP levels 200 pg/ml appeared to have no
dvantage in being admitted.
CREENING FOR LV DYSFUNCTION. Recent studies have
emonstrated that NPs are an important cost-effective tool
o diagnose LV dysfunction, either in conjunction with an
chocardiogram or, in certain patients, in lieu of echocar-
iography (13,14,15). One of the great contributions of
ichards et al. (2) is specific thresholds for both peptides
hat the practicing clinician can use in detecting LV
ysfunction in stable ischemic heart disease patients. With
egards to BNP, our own data are in strong agreement with
ichards et al. (2), as we found that BNP levels in the range
f 40 to 70 pg/ml allow us to detect echo abnormalities in
NP) levels in the acute dyspneic patient. ECG  electrocardiogram; CHF
Cardiovasc Med 2002;3:S13.atients with a high prevalence of disease but who are
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January 3, 2006:61–4 Editorial Commentsymptomatic. In addition, we recently found that if we
ove the cut point even lower, to 20 pg/ml, we can find a
roup of patients who are very unlikely to have significant
entricular dysfunction (particularly systolic) during subse-
uent echocardiography. To this end, we have published an
lgorithm that may be useful for screening in the outpatient
etting (16) (Fig. 3).
ANAGEMENT OF CHF. Though not yet a Food and Drug
dministration-approved indication, the use of NPs for
onitoring volume status and treatment in patients admit-
ed for CHF is promising. The fact that NPs have short
igure 2. Optimal cut points for NTproBNP for diagnosing acute congesti
ailure diagnosis only. NPV  negative predictive value; PPV  positive p
3).
igure 3. Algorithm for using B-type natriuretic peptide (BNP) testing in
eart failure; ED  emergency department; EKG  electrocardiogram; HF 
myocardial infarction. Adapted from Silver et al. (17).alf-lives (20 min for BNP, 120 min for NT proBNP) and
asy-to-measure levels and are surrogates for wedge pres-
ure, volume, New York Heart Association functional class,
nd prognosis suggests their usefulness in this setting. Last
ear, a consensus panel met regarding the use of NPs (17).
lthough BNP was mainly discussed, many of the consen-
us conclusions may apply to NTproBNP as well. The
ollowing are three consensus statements with regard to
NP levels in the hospital:
Although in a given patient, BNP level does not always
correlate to wedge pressure, in a patient admitted with
rt failure. The cut points listed in the figures are for acute congestive heart
tive value. Adapted from Januzzi JL, et al. Am J Cardiol 2005;95:948–54
rimary care setting. CAD  coronary artery disease; CHF  congestiveve hea
redicthe p
heart failure; JVD  jugular venous distension; LV  left ventricular; MI
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Editorial Comment January 3, 2006:61–4heart failure, high filling pressures secondary to volume
overload, and a high BNP level (decompensated or “wet”
BNP), a treatment-induced decrease in wedge pressure
will almost always be associated with a rapid drop in
BNP levels as long as the patient is maintaining adequate
urine output.
Levels of BNP do not need to be drawn every day that a
patient is in the hospital. Rational use of BNP levels
would be on admission, after a major treatment effect
(usually after 24 h of treatment), and when discharge is
contemplated (and euvolemia reached).
Failure of BNP levels to decrease during hospitalization
is a poor prognostic sign, suggesting consideration of
more intensive monitoring, treatments, and follow-up.
onclusions. In just five short years, NP levels have
ermeated not just emergency medicine and cardiology, but
ave generated interest among those involved in internal
edicine, family medicine, and pediatrics. As typically
appens in science, the explosion of emerging knowledge
ften outstrips practitioners’ ability to integrate data into
heir personal infrastructure of clinical practice. Natri-
retic peptides are not stand-alone tests. Much as tropo-
in testing must take into account the clinical features of
cute coronary syndrome as well as electrocardiographic
ndings, NP measurements need to be evaluated in concert
ith a careful history, physical exam, and other laboratory
ests to obtain maximum benefit. There is clearly a learning
urve for using NP levels. Articles that elevate the knowl-
dge base considerably, such as that of Richards et al. (2), as
ell as routine use of these peptides in our practice, ensure
hat our learning will be complete.
eprint requests and correspondence: Dr. Alan Maisel, Univer-
ity of California, San Diego, 3350 La Jolla Village Drive, San
iego, California 92161. E-mail: amaisel@ucsd.edu.
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